Research

Neurotransmitter functions are chiefly controlled by 7 and 12-transmembrane proteins that can serve as molecular targets for drug actions. Nature utilizes combinations of these receptors/transporters to maintain balance in the CNS. Neuropsychiatric disorders usually result from a dysfunction of more than one transmembrane receptor/transporter, suggesting that drugs with dual or multiple actions may be most effective.

scientist injecting sample into test tube

Utilizing its proprietary chemistry approach, Prexa systematically evaluated monoamine transporter selectivity and potency of molecules with differing chiralities. From this strategy, Prexa generated novel families of high affinity mono-selective dopamine transporter inhibitors, dual selective dopamine and norepinephrine transporter inhibitors and other unique tri-selective dopamine, norepinephrine and serotonin inhibitors. Prexa continues to characterize its portfolio of novel monoaminergic transport inhibitors. Prexas mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.